Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cancer care

Nivolumab should be standard for head and neck cancer

Treatment with nivolumab improves survival in patients with head and neck squamous-cell carcinoma compared with chemotherapy, study finds.

Histopathology stain of squamous-cell carcinoma

Source: Wikimedia Commons

Nivolumab improved survival in patients with head and neck squamous cell carcinoma compared with platinum-based chemotherapy

Patients with recurrent or metastatic head and neck squamous-cell carcinoma (SCCHN) have a poor prognosis and limited treatment options. 

A team of researchers explored the effect of nivolumab, a monoclonal antibody approved for use in metastatic melanoma and lung cancer, in 361 SCCHN patients whose disease had progressed on platinum-based chemotherapy. 

They found that 36% of patients randomly assigned to nivolumab were alive after one year compared with 17% of patients who received chemotherapy with methotrexate, docetaxel or cetuximab. The median overall survival was 7.5 months and 5.1 months, respectively. 

The researchers, who reported their findings at the American Association for Cancer Research 2016 Annual Meeting (16–20 April 2016)[1], say nivolumab is the first immunotherapy to improve survival in SCCHN and should become standard of care for these patients.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201080

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Histopathology stain of squamous-cell carcinoma

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.